Co-Diagnostics to Showcase TB Test at Stop TB Partnership Summit

Event summary

  • Co-Diagnostics invited to present at Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.
  • Company to showcase Co-Dx MTB test on Co-Dx PCR platform during roundtable with U.S. government agencies and private sector companies.
  • WHO guidance on near-point-of-care molecular diagnostics aligns with Co-Diagnostics' testing platform and Co-Dx MTB NPOC test.
  • Co-Dx PCR platform, including PCR Home®, PCR Pro®, and mobile app, is subject to regulatory review and not yet available for sale.

The big picture

Co-Diagnostics' invitation to the Stop TB Partnership Summit underscores the growing emphasis on near-point-of-care diagnostics in the global fight against tuberculosis. The alignment of its Co-Dx MTB test with WHO guidance positions the company to capitalize on the increasing demand for accessible and efficient TB testing solutions. The event serves as a critical platform for the company to demonstrate its technology to key stakeholders and potentially secure partnerships that could accelerate its market entry and adoption.

What we're watching

Regulatory Approval
The pace at which Co-Diagnostics secures FDA and other regulatory approvals for its Co-Dx PCR platform will determine its market entry timeline.
Market Adoption
Whether the Co-Dx MTB test can gain traction among global stakeholders following its presentation at the summit.
Strategic Partnerships
How the company leverages the Stop TB Partnership Summit to forge new alliances and expand its pipeline of TB products.